SYSTEMATIC REVIEW

Efficacy and safety of platelet-rich plasma combined with hyaluronic acid versus platelet-rich plasma alone for knee osteoarthritis: a systematic review and meta-analysis

Qing Zhang, Tuodong Liu, Yuan Gu, Yongquan Gao and Jiangdong Ni*

Abstract

Purpose: To systematically evaluate the curative efficacy and safety of platelet-rich plasma (PRP) combined with hyaluronic acid (HA) in the treatment of knee osteoarthritis (KOA), comparing with platelet-rich plasma alone.

Methods: Cochrane Library, PubMed, China National Knowledge Infrastructure (CNKI) and Embase were searched for randomized controlled trials (RCTs) and cohort studies regarding the efficacy and safety of platelet-rich plasma (PRP) combined with hyaluronic acid (HA) in the treatment of knee osteoarthritis (KOA) comparing with platelet-rich plasma alone before January 15, 2022. The methodological quality of the ultimately included studies was assessed comprehensively, and meta-analysis was implemented using RevMan 5.3 software.

Results: Thirteen articles (9 RCTs, 4 cohort studies), including 1118 patients, were covered. There was no significant difference between the PRP+HA therapy and PRP-alone therapy in VAS scores at 3 months, 6 months and 12 months, WOMAC total scores at 3 months and KOOS at 1 month and 6 months. Compared with PRP-alone therapy, PRP+HA therapy was associated with significantly better improvement in VAS scores at 1 month, WOMAC total scores at 6 months, KOOS at 3 months, IKDC scores at 6 months and Lequesne index scores at 3 and 6 months. However, the smallest treatment effect of VAS scores, WOMAC total scores, KOOS and IKDC scores did not exceed the minimum clinically important difference (MCID). However, PRP+HA therapy got a greater reduction in the rate of adverse events, compared with PRP-alone therapy.

Conclusion: The results of this meta-analysis indicated that PRP+HA therapy was not found to be superior to PRP-alone therapy in pain relief and function improvement for patients with KOA. However, combined PRP with HA injections was generally safer than PRP injections alone, by assessing the incidence of adverse events.

Keywords: Platelet-rich plasma, Hyaluronic acid, Knee osteoarthritis, Meta-analysis

Background

Knee arthritis (KOA) refers to a common joint disease characterized by knee cartilage degeneration and joint space stenosis [1]. Knee arthritis has been found as a vital cause of knee pain and progressive loss of joint function [2]. A number of methods have been suggested for
treat KOA, which consist of pharmacological, nonpharmacological and surgical therapy [3]. However, there are no clear drugs or methods that have been proved to change the development process of KOA [4]. Intra-articular injection therapy is recognized as a feasible nonoperative treatment of KOA and traditionally included hyaluronic acid (HA) or glucocorticoid as means of promoting joint lubrication, reducing joint inflammation, and reducing pain [5–7]. Recently, clinicians have treated KOA with intra-articular injections of hyaluronic acid (HA), platelet-rich plasma (PRP) and bone marrow concentrate (BMAC) [8].

Hyaluronic acid (HA) refers to a naturally occurring glycosaminoglycan found in synovial fluid that increases viscosity and lubricates joints. It has been proven to treat KOA through limiting inflammatory pathways and reducing pain of knee [9, 10]. The American College of Rheumatology (ACR) has recommended the injection of intra-articular HA in patients in 2012 [11].

Platelet-rich plasma (PRP) refers to a type of autologous blood extract, containing high concentration of platelets. It contains a wide variety of growth factors and other bioactive molecules, which are considered to control the aberrant inflammatory processes and thus to facilitate tissue healing [12]. Intra-articular injection of HA is not only expensive, but also has an unsatisfactory effect on inflammation. Even though there is a lack of definitive recommendations on PRP, the encouraging results reported by preliminary clinical evidences have allowed numerous clinicians to consider PRP as effective treatment for KOA [13].

Over the past few years, PRP + HA treatment has been progressively employed as a therapy of KOA. A number of articles have suggested that PRP + HA treatment might provide a synergistic effect, thus alleviating pain, ameliorating joint function and inhibiting the progress of KOA [14]. However, the number of articles, comparing the efficacy and safety of the combination therapy versus PRP-alone therapy, is limited. The aim of the meta-analysis was to systematically assess the curative efficacy and safety of PRP + HA therapy in the treatment of knee osteoarthritis (KOA), comparing with platelet-rich plasma alone.

**Methods**

**Search strategy**

This meta-analysis was following the Preferred Reporting Items for Systematic Review and Meta-Analysis statement (Additional file 1: PRISMA) [15]. Two independent researchers (QZ and YG) searched PubMed, EMBASE, Cochrane Library and CNKI up to January 15, 2022. Search terms were used including “platelet-rich plasma,” “hyaluronic acid,” “knee osteoarthritis.” The database retrieval strategies are illustrated in Additional file 2.

**Literature screening and data extraction**

The relevant data from articles were abstracted by two researchers (TDL and YQG) independently using a prepared data extraction form. Information that was extracted from the selected studies consisted of publication year, authors, patient characteristics, study design, number of included patients, interventions, follow-up time, as well as outcomes. Any disagreement would be resolved through discussion with a third investigators.

**Risk of bias assessment**

Two independent researchers (TDL and YQG) evaluate the risk of bias for RCTs by using the Cochrane Risk of Bias tool [16]. Each study was evaluated based on the following 7 areas: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, as well as other biases. Two independent researchers (TDL and YQG) performed the quality assessment of cohort studies by using Newcastle–Ottawa Scale (NOS). The scale was divided into 3 items: selection, comparability, and exposure.

**Statistical analysis**

RevMan 5.3 software was employed for analysis. Risk ratio (RR) with 95% confidence interval (95% CI) was used for the dichotomous variables and mean difference (MD) with 95% CI for the continuous variables. When \( P<0.05 \), the difference would be significantly significant. Fixed effects model was adopted to analyze data if there was low heterogeneity (\( p>0.10, I^2<50\% \)); otherwise, random effects model would be used. The pooled effect sizes were compared with their minimum clinically important differences (MCIDs), defined as the smallest difference perceived as importantly the average patient [17]. If treatment effects meet or exceed MCID, treatment should be changed unless side effects or costs are excessive [18].

**Inclusion and exclusion**

**Inclusion criteria**

1. Studies: RCTs or cohort studies were included
2. Population: patients diagnosed with KOA
3. Intervention: PRP + HA therapy; Comparator: PRP treated alone; and
4. At least one of the outcome indicators, including Visual Analogue Scale (VAS) scores, Western Ontario and McMaster Universities Arthritis Index (WOMAC) total scores, Knee Injury and Osteoarthritis Outcome Scores (KOOSs), International Knee Documentation Committee (IKDC) scores, Lequesne index scores, as well as adverse events.
Exclusion criteria
(1) The studies that were not associated with treatment for KOA; (2) Laboratory or animal articles; (3) Duplicate publications, secondary publications or articles with similar data; and (4) Reviews, meeting abstracts, case reports, letters to the editor or commentaries.

Results
Literature searching
A total of 515 related articles were identified. After eliminating duplicates, a total of 325 related articles initially identified. Then, 22 articles were retrieved for full text, after screening titles and abstracts. Nine RCTs [14, 19–26] and 4 cohort studies [27–30] were eventually included in this study. The above articles hold a total patient sample size of 1118. Figure 1 presents the article screening process and results.

Table 1 lists the basic characteristics of the covered articles. The ages of participants were primarily concentrated, ranging from 40 to 60 years. The Kellgren and Lawrence grading scales were I to IV. Follow-up time reported ranged from for 5 weeks to 24 months. There were some differences in the preparation of PRP among the included literatures, which may have affected the efficacy of KOA treatment. Additional file 3 presents the results.

Quality assessment of the included literature
Among the 9 RCTs, 8 articles explicitly reported the specific method of random assignment, and one study only mentioned randomness without specifying the specific
### Table 1: Important characteristics of patients enrolled in the included studies

| Study, year | Study design | Sample size | Gender (M/F) | Age, years | Kellgren-Lawrence score (I:II:III:IV) | Clinical outcomes | Follow-up periods |
|-------------|--------------|-------------|--------------|------------|---------------------------------------|------------------|------------------|
| Zhao [19]   | RCT          | 62          | 35/27        | 55.73 ± 7.18 | 5632 ± 8.13                         | –                | 5 weeks          |
| Rao [20]    | RCT          | 20          | 20           | 73.3 ± 7.2  | 733 ± 7.2                            | –                | 5 weeks          |
| Ke [21]     | RCT          | 50          | 25/25        | 57.80 ± 6.90 | 539 ± 7.1                           | 5:11:20:14, 6:12:20:12 | 12 months       |
| Ding [22]   | RCT          | 20          | 2/18         | 56.75 ± 9.536 | 62.11 ± 12.50  | 9:6:5:0, 10:11:6:0 | 12 months       |
| Yu [14]     | RCT          | 104         | 46/50        | 46.50 ± 7.50 | 46.20 ± 8.60                          | –                | 12 months        |
| Jacob [23]  | RCT          | 20          | 31           | –          | –                                    | –                | 6 months         |
| Sun [24]    | RCT          | 39          | 21/18        | 17/22      | 606 ± 8.4, 584 ± 8.1                  | 0.3900, 0.3900   | 6 months         |
| Lana [25]   | RCT          | 33          | 6/27         | 62 ± 6.1   | 60.9 ± 7                             | 5:14:0, 9:14:13:0 | 6 months         |
| Xu [26]     | RCT          | 48          | 40           | –          | 579 ± 4.1, 56.9 ± 4.2                 | 0.2523, 0.19:21  | 24 months        |
| Huang [27]  | Co, P        | 31          | 8/23         | 63 ± 7.02  | 65.03 ± 7.10                         | 0.10:10:11, 0.91:15:9 | 6 months       |
| Guo [28]    | Co, R        | 63          | 45/18        | 61.2 ± 9.6  | 60.7 ± 10.1                          | 17:28:18:0, 15:31:17:0 | 12 months   |
| Abate [29]  | Co, R        | 40          | 31/9         | 56.7 ± 11.2 | 60.90 ± 9.0                          | 0.23:17:0, 0.19:21:0 | 6 months         |
| Palco [30]  | Co, R        | 28          | 23           | 62.71 ± 7.88, 54.04 ± 10.4 | 0.82:00, 0.10:13:0 | 12 months       |

**Notes:**

- **RCT:** Randomized controlled trial, **Co:** Cohort study, **P:** Prospective study, **R:** Retrospective study
- **PRP:** Platelet-rich plasma, **HA:** Hyaluronic acid
- **PR:** Platelet-poor plasma
- **VAS scores:** Visual Analog Scale scores
- **WOMAC total scores:** Western Ontario and McMaster Universities Osteoarthritis Index total scores
- **KOOS:** Knee injury and osteoarthritis outcome scores
- **IKDC scores:** International Knee Documentation Committee scores
- **Lequesne index scores:** Lequesne index scores
- **Adverse events**

---

RCT: randomized control trial, Co: Cohort study, P: prospective study, R: retrospective study, PRP: platelet-rich plasma, HA: hyaluronic acid.
method. Two out of 9 studies did not clarify the allocation concealment. For blinding of participants and personnel, the risk of bias was high in 1 out of 9 studies, was unclear in 5 out of 9 studies and was low in 3 out of 9 studies. For blinding of outcome assessment, the risk of bias was unclear in 5 out of 9 studies and was low in 4 out of 9 studies. For incomplete outcome data, selective reporting and other bias, all studies had low risk of bias. (Figs. 2 and 3). For cohort studies, the mean NOS for the 4 cohort studies was 8.25 (Table 2).

MCID
Based on previous work, the MCID for both the pain VAS scores and the WOMAC total scores was set at 20% [19–22]. Therefore, based on the baseline values of each outcome in the included studies, the MCID of the pain VAS scores was calculated to be 1.16, and the WOMAC total score was 7.86. In addition, the mean difference between the two groups was compared with the MCID for each score reported in the literature: 11.5/100 for the IKDC scores [31] and 10/100 for the KOOS subscale [32].

Outcomes of the meta-analysis
VAS scores
A total of 5 articles [19, 20, 23, 24, 29], including 393 patients, assessed VAS scores 1 month post-treatment. For the comparison of VAS scores at 1 month post-treatment between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group, the smallest treatment effect (−0.65) did not exceed the MCID (1.16). The analysis suggested that compared with the control group, the VAS scores of the experimental group at 1 month post-treatment were statistically significant, but not clinically significant (MD = −0.65, 95% CI −1.31 to −0.00, p = 0.05) (Fig. 4).

A total of 4 articles [22, 24, 29, 30], enrolling 256 patients, assessed VAS scores at 3 months post-treatment. For the comparison of VAS scores at 3 months post-treatment between the experimental (PRP + HA
therapy) group and the control (PRP-alone therapy) group, the smallest treatment effect (−0.21) did not exceed the MCID (1.16). The analysis suggested that the difference between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group was neither statistically significant, but not clinically significant (MD = −0.21, 95% CI −0.57 to 0.15, p = 0.25) (Fig. 5).

A total of 4 articles [22–24, 29], enrolling 276 patients, assessed VAS scores at 6 months post-treatment. For the comparison of VAS scores at 6 months post-treatment between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group, the smallest treatment effect (−0.34) did not exceed the MCID (1.16). The analysis suggested that the difference between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group was neither statistically significant, but not clinically significant (MD = −0.34, 95% CI −0.74 to 0.05, p = 0.09) (Fig. 6).

A total of 2 articles [28, 30], enrolling 177 patients, assessed VAS scores at 12 months post-treatment. For the comparison of VAS scores at 12 months post-treatment between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group, the smallest treatment effect (−0.29) did not exceed the MCID (1.16). The analysis suggested that the difference between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group was neither statistically significant, but not clinically significant (MD = −0.29, 95% CI −0.83 to 0.25, p = 0.30) (Fig. 7).

### Table 2: Newcastle–Ottawa Scale for risk of bias assessment of cohort studies included in the meta-analysis

| Study        | Selection Comparability | Outcome Overall |
|--------------|-------------------------|-----------------|
| Representativeness of exposed cohort | Selection of non-exposed | Ascertainment of exposure | Outcome not present at start | Adequate Follow-Up Length | Adequacy of Follow-Up |
| Huang [27]   | ★ ★ ★ ★ ★★ ★ ★         | ★★★             | ★                 | ★               | ★               | 9 |
| Guo [28]     | ★ ★ ★ ★ ★★ ★ ★         | ★★★             | ★                 | ★               | ★               | 8 |
| Abate [29]   | ★ ★ ★ ★ ★★ ★ ★         | ★★★             | ★                 | ★               | ★               | 9 |
| Palco [30]   | ★ ★ ★ ★ ★★ ★ ★         | ★★★             | ★                 | ★               | ★               | 7 |

![Fig. 4](image1.png)

**Fig. 4** Forest plot and meta-analysis of VAS scores (1 month)

![Fig. 5](image2.png)

**Fig. 5** Forest plot and meta-analysis of VAS scores (3 months)
**WOMAC total scores**
A total of 3 articles [21, 22, 24], including 225 patients, assessed WOMAC total scores at 3 months post-treatment. For the comparison of WOMAC total scores at 3 months post-treatment between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group, the smallest treatment effect (−2.09) did not exceed the MCID (7.86). The analysis showed that compared with the control group, the WOMAC total scores of the experimental group at 3 months post-treatment was neither statistically significant, but not clinically significant (MD = −2.09, 95% CI = −6.82 to 2.64, p = 0.39) (Fig. 8).

A total of 3 articles [21, 22, 24], enrolling a total of 225 patients, assessed WOMAC total scores at 6 months post-treatment. For the comparison of WOMAC total scores at 6 months post-treatment between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group, the smallest treatment effect (−2.66) did not exceed the MCID (7.86). The analysis suggested that compared with the control group, the WOMAC total scores of the experimental group at 6 months post-treatment were statistically significant, but not clinically significant (MD = −2.66, 95% CI = −5.36 to 0.03, p = 0.05) (Fig. 9).

**KOOS**
Two articles [27, 29], including 144 patients, reported KOOS at 1 month after the treatment. For the comparison of KOOS at 1 month after the treatment between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group, the smallest treatment effect (3.84) did not exceed the MCID (10). As revealed by the results, the difference between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group was neither statistically significant, but not clinically significant (MD = 3.84, 95% CI = 1.67 to 9.35, p = 0.17) (Fig. 10).

---

**Fig. 6** Forest plot and meta-analysis of VAS scores (6 months)

**Fig. 7** Forest plot and meta-analysis of VAS scores (12 months)

**Fig. 8** Forest plot and meta-analysis of WOMAC total scores (3 months)
Two articles [27, 29], enrolling 144 patients, reported KOOS at 3 months after the treatment. For the comparison of KOOS at 3 months after the treatment between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group, the smallest treatment effect (6.06) did not exceed the MCID (10). The pooled results revealed that compared with the control group, the KOOS of the experimental group at 3 months post-treatment was statistically significant, but not clinically significant (MD = 6.06, 95% CI −0.82 to 11.30, p = 0.02 < 0.05) (Fig. 11).

KOOS was assessed by 2 articles [27, 29] in 144 patients at 6 months post-treatment. For the comparison of KOOS at 6 months after the treatment between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group, the smallest treatment effect (1.81) did not exceed the MCID (10). The analysis suggested that the difference between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group was neither statistically significant, but not clinically significant (MD = 1.81, 95% CI −3.15 to 6.77, p = 0.48) (Fig. 12).

IKDC scores
IKDC scores were assessed 2 articles [21, 23] in 171 patients at 6 months post-treatment. For the comparison of IKDC scores at 6 months post-treatment between the experimental (PRP + HA therapy) group and the control (PRP-alone therapy) group, the smallest treatment effect (5.01) did not exceed the MCID (11.5). The results suggested that compared with the control group, the IKDC scores of the experimental group at 6 months post-treatment were statistically significant, but not clinically significant (MD = 5.01, 95% CI 1.36 to 8.67, p = 0.007 < 0.05) (Fig. 13).

Lequesne index scores
A total of 2 articles [21, 22], including 147 patients, assessed Lequesne index scores at 3 months post-treatment. The analysis suggested that the scores of the experimental (PRP + HA therapy) group were significant, but not clinically significant (MD = 1.81, 95% CI −3.15 to 6.77, p = 0.48) (Fig. 12).
lower than that of the control (PRP-alone therapy) group. (MD = −1.06, 95% CI = −1.61 to −0.51, \( p = 0.0001 < 0.05 \)) (Fig. 14).

Two articles [21, 22], including 147 patients, assessed Lequesne index scores at 6 months post-treatment. The analysis showed that the scores of the experimental (PRP + HA therapy) group were lower than that of the control (PRP-alone therapy) group (MD = −1.46, 95% CI = −2.01 to −0.90, \( p = 0.00001 < 0.05 \)) (Fig. 15).

**Adverse events**

Nine articles [14, 21, 22, 25–27, 29, 33, 34] with 859 patients reported the incidence of adverse events. The pooled results demonstrated that in terms of adverse events, PRP + HA therapy was generally safer than PRP injections alone (RR = 0.53, 95% CI 0.35 to 0.81, \( p = 0.003 < 0.05 \)) (Fig. 16).
Discussion

KOA refers to one of the most common articular diseases, posing a serious hazard to the physical and mental health of patients. It has been recognized as the main cause of disability in the elderly [35]. Over the past few years, there have been a series of clinical trials comparing the effectiveness of different injections for treating KOA [36–38]. The majority of the above articles directly compared PRP versus HA, assessing their efficacy and safety using a considerable number of indicators, including VAS, WOMAC, or IKDC scores [39]. At present, there has been controversy relating to the clinical effect comparison between PRP and HA. There have been some articles concluding that PRP therapy could result in greater and longer-lasting improvements in alleviating pain, ameliorating the function of knee joint, in comparison with HA [37, 40]. However, Sun et al. [38] concluded that the difference between PRP groups and HA groups in the clinical improvements of KOA was not significant. There have been numerous systematic reviews and meta-analyses, synthesizing preliminary studies and evaluating improvements in knee pain and function, generally confirming that PRP is beneficial for pain relief, and functional improvement, compared with HA and corticosteroids [41, 42].

During osteoarthritis, the synovium undergoes extensive changes, typically characterized by inflammatory pathology [43]. HA, a joint lubricant, has been extensively employed in clinical practice. HA has been confirmed to down-regulate pro-inflammatory factors (e.g., NFkB and PGE2), as well as proteases and proteinases known to break down the joint matrix [44]. HA is considered to be involved in proteoglycan and glycosaminoglycan synthesis, chondroprotection, as well as anti-inflammation [45]. Intra-articular injections of HA are capable of physically lubricating the articular surface, biologically nourishing articular cartilage, reducing wear of articular cartilage and facilitating endogenous HA synthesis, thus delaying further joint disease [45–47]. Intra-articular injection of PRP was considered to have the effect of alleviating knee pain, and ameliorating knee function with high safety [48]. PRP is capable of controlling the above inflammatory processes by releasing cytokines and growth factors [43]. PRP is capable of facilitating cell proliferation, collagen synthesis and vascularity, inducing a regenerative response and improving the metabolic function of damaged tissues [38, 49]. Over the past few years, the combination of PRP and HA has been considered to be more effective than PRP or HA alone in alleviating pain and ameliorating knee function. Razaq et al. suggested that PRP + HA therapy can exert a large synergistic effect on improving the outcome of moderate and severe KOA [50]. The combination therapy is capable of effectively relieving pain, improving function and reducing adverse reactions [26]. The synergistic effect is mainly through specific mediators (CD44, TGF-β1) to change the role of inflammatory cytokines in the degeneration of chondrocytes, so as to promote cartilage regeneration and inhibit inflammatory response [51]. The mechanism of this synergistic effect should be studied in depth.

There are some systematic reviews and meta-analyses, synthesizing primary studies and assessing improvements in pain and function. Zhao et al. found that compared with PRP alone, PRP + HA may have better clinical efficacy in the treatment of KOA [52]. Aw et al. found that compared with PRP alone, PRP + HA may be effective at providing pain relief and improvement in function up to 1 year following administration in the treatment of KOA [53]. However, there was a discrepancy between our conclusions and theirs. Over the past few decades,
the concept of MCID has emerged in the outcome literature [54–57]. A clinically important difference is defined as a change or difference in an outcome measure deemed important and beneficial by the clinician or patient [17]. Our meta-analysis showed that the differences of VAS scores, WOMAC total scores, IKDC scores and KOOS between the two groups were less than their MCID values (MICD values: 1.16 for VAS scores, 7.86 for WOMAC total scores, 11.5 for IKDC scores and 10 for KOOS). Therefore, the statistical differences between the therapies found by VAS scores, WOMAC total scores, IKDC scores and KOOS were unlikely to have clinical significance. Although we found no literature on MCID for Lequesne index scores, based on the results of VAS scores, WOMAC total scores, KOOS, IKDC scores, we consider that PRP + HA therapy was not found to be superior to PRP-alone therapy in pain relief and function improvement for patients with KOA. We note that our conclusions differ from those of Zhao et al. and Aw et al. Probably because in this meta-analysis, we did not rely solely on statistical significance to measure the difference between the PRP + HA groups and the PRP-alone groups, we also used the MCID to help judge the clinical difference between the two groups.

However, some limitations were inevitable. Firstly, 4 articles were cohort studies, which may lead to the heterogeneity of the comprehensive index. Secondly, most of the articles had limited follow-up time, and the long-term curative efficacy and safety of PRP + HA therapy cannot be assessed. Thirdly, due to the small number of the selected studies, publication bias cannot be assessed by funnel plot. Fourthly, the concentrations of PRP used in the articles varied from study to study and may affect efficacy in the treatment of KOA.

Conclusion
The results of this meta-analysis indicated that PRP + HA therapy were not found to be superior to PRP-alone therapy in pain relief and function improvement for patients with KOA. However, combined PRP with HA injections was generally safer than PRP injections alone, by assessing the incidence of adverse events.

Research registration Unique Identifying number (UIN)
1. Name of the registry: PROSPERO
2. Unique Identifying number or registration ID: CRD42022302539
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=302539

Abbreviations
PRP: Platelet-rich plasma; HA: Hyaluronic acid; KOA: Knee osteoarthritis; CNKI: China National Knowledge Infrastructure; RCT s: Randomized controlled trials; VAS: Visual analogue scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index; KOOS: Knee Injury and Osteoarthritis Outcome Score; IKDC: International Knee Documentation Committee; MCID: Minimum clinically important difference.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13018-022-03398-6.

Acknowledgements
Not applicable in this section.

Author contributions
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 5 April 2022 Accepted: 10 November 2022
Published online: 19 November 2022

References
1. Phillips M, Vannabouathong C, Devji T, Patel R, Gomes Z, Patel A, et al. Differentiating factors of intra-articular injectables have a meaningful impact on knee osteoarthritis outcomes: a network meta-analysis. Knee Surg Sports Traumatol Arthrosoc. 2020;28(9):3031–9.
2. Kennedy MI, Whitney K, Evans T, LaPrade RF. Platelet-rich plasma and cartilage repair. Curr Rev Musculoskelet Med. 2018;11(4):573–82.
3. Charlesworth J, Fitzpatrick J, Perera NKP, Orchard J. Osteoarthritis - a systematic review of long-term safety implications for osteoarthritis of the knee. BMC Musculoskelet Disord. 2019;20(1):151.
4. Hussain SM, Neilly DW, Baliga S, Patil S, Meek R. Knee osteoarthritis: a review of management options. Scott Med J. 2016;61(1):7–16.

Appendix 1. Additional file 1. PRISMA 2020 Checklist.
Additional file 2. Supplementary material 1.
Additional file 3. Supplementary material 2.
5. Campbell KA, Erickson BJ, Saltzman BM, Mascarenhas R, Bach BR Jr, Cole BJ, et al. Is local viscosupplementation injection clinically superior to other therapies in the treatment of osteoarthritis of the knee: a systematic review of overlapping meta-analyses. Arthroscopy. 2015;31(10):2036-46. e14.

6. Yafatia NA, Weber K. Corticosteroids and hyaluronic acid injections. Clin Sports Med. 2019;38(8):11–15.

7. Waddell DD. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging. 2007;24(8):629–42.

8. Aw AAL, Leeu JI, Tao X, Bin Abd Razak HR. Comparing the efficacy of dual platelet-rich plasma (PRP) and hyaluronic acid (HA) therapy with PRP alone in the treatment of knee osteoarthritis: a systematic review and meta-analysis. J Exp Orthop. 2021;8(1):101.

9. Vincent P. Intra-articular hyaluronic acid in the symptomatic treatment of knee osteoarthritis: a meta-analysis of single-injection products. Curr Ther Res Clin Exp. 2019;90:39–51.

10. Dahl LB, Dahl IM, Engström-Laurent A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis. 1985;44(12):817–22.

11. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American college of rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2020;72(2):149–62.

12. Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: a review and author’s perspective. J Cutan Aesthet Surg. 2014;7(4):189–97.

13. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46–54.

14. Yu W, Xu P, Huang G, Ji U. Clinical therapy of hyaluronic acid combined with platelet-rich plasma for the treatment of knee osteoarthritis. Exp Ther Med. 2018;16(3):2119–25.

15. Page MJ, McKenzie JE, Bussuyt PM, Bouton J, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.

16. Higgins JP, Altman DG, Gatchicine PC, Juni P, Moher D, Oxman AD, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

17. Dogarsya Erdogan B, Leung YY, Pohl C, Tennyson F, Sellen F, Cenacchi A, et al. Platelet-rich plasma versus hyaluronic acid for the treatment of knee osteoarthritis: results of an open-label trial. Arch Bone Jt Surg. 2021;9(5):487–95.

18. Roos EM, Lohmander LS. The knee injury and osteoarthritis outcome score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes. 2003;1:64.

19. Sun SF, Lin GC, Hsu CW, Lin HS, Liu IS, Wu SY. Comparing efficacy of intra-articular single crosslinked Hyaluronan (HYAJOINT Plus) and platelet-rich plasma (PRP) versus PRP alone for treating knee osteoarthritis. Sci Rep. 2021;11(1):140.

20. Guo Y, Yuan L, Yao S, Yu H, Wang P, Lu H, et al. Treatment of knee osteoarthritis with platelet-rich plasma plus hyaluronic acid in comparison with platelet-rich plasma only. Int J Clin Exp Med. 2016;9(6):12085–90.

21. Lo SR, Lam ASP, Ho SW, Fung KF, Yeung WS. Efficacy of autologous platelet-rich plasma and the combination of both in the treatment of knee osteoarthritis. Chin J Osteopora. 2019;25(2).

22. Xiao MD, Lu J, Wang YF, Li X, Jia QL, Zhao DX, et al. Hyaluronic acid and platelet rich plasma and the combination of both in the treatment of moderate and mild osteoarthritis of the knee. J Stem Cells Regen Med. 2016;12(2):69–78.

23. Xu Z, He Z, Shui L, Li X, Ma M, Ye C. Intra-articular platelet-rich plasma combined with hyaluronic acid injection for knee osteoarthritis is superior to platelet-rich plasma or hyaluronic acid alone in inhibiting inflammation and improving pain and function. Arthroscopy. 2021;37(3):903–15.

24. Huang K, Wu Z, Zhang Z, Chang W, Wang G, Sun Q. Hyaluronic acid, platelet rich plasma and the combination of both in the treatment of osteoarthritis of the knee. Chin J Osteopora. 2019;25(2).

25. Guo Y, Hu Y, Yuan L, Yao S, Yu H, Wang P, et al. Treatment of knee osteoarthritis with platelet-rich plasma plus hyaluronic acid in comparison with platelet-rich plasma only. Int J Clin Exp Med. 2016;9(6):12085–90.

26. Abate M, Verna S, Schiavone C, Di Gregorio P, Salini V. Efficacy and safety profile of a compound composed of platelet-rich plasma and hyaluronic acid in the treatment for knee osteoarthritis (preliminary results). Eur J Orthop Surg Traumatol. 2015;25(8):1321–6.
44. Peck J, Slovec A, Miro P, Vij N, Traube B, Lee C, et al. A comprehensive review of viscosupplementation in osteoarthritis of the knee. Orthop Rev. 2021;13(2):2549.

45. Doymus T, Mutlu S, Dernek B, Komur B, Aydogmus S, Kesiktas FN. Choice of intra-articular injection in treatment of knee osteoarthritis: platelet-rich plasma, hyaluronic acid or ozone options. Knee Surg Sports Traumatol Arthrosc. 2017;25(2):485–92.

46. Maheu E, Bannuru RR, Herrero-Beaumont G, Allali F, Bard H, Migliore A. Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: results of an extensive critical literature review. Semin Arthritis Rheum. 2019;48(4):563–72.

47. Richette P. Hyaluronic acid: still useful in knee osteoarthritis? Joint Bone Spine. 2017;84(6):655–6.

48. Du W, Cui H-P, Fu B-S, Li W, Liu Q, Zhong Y-X, et al. Platelet rich plasma intra-articular and extra-articular injection for the treatment of knee osteoarthritis. Zhongguo gu Shang = China J Orthop Traumatol. 2020;33(3):209–13.

49. Szwedowski D, Szczepanek J, Paczesny Ł, Zabrzyński J, Gagat M, Mobasheri A, et al. The effect of platelet-rich plasma on the intra-articular microenvironment in knee osteoarthritis. Int J Mol Sci. 2021;22(11):5492.

50. Razaq MA, Qasim AA, Assim TM, Ramzi R. Combination of platelet-rich plasma and hyaluronic acid in the treatment of moderate and severe osteoarthritis of the knee joint. Rheumatology. 2020;28(4):31–5.

51. Anda J, Abate M. Knee osteoarthritis: hyaluronic acid, platelet-rich plasma or both in association? Expert Opin Biol Ther. 2014;14(5):635–49.

52. Zhao J, Huang H, Liang G, Zeng L-F, Yang W, Liu J. Effects and safety of the combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) in the treatment of knee osteoarthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2020. https://doi.org/10.1186/s12891-020-03262-w.

53. Aw AAL, Leeu JJ, Tao X, Razak HRBA. Comparing the efficacy of dual platelet-rich plasma (PRP) and hyaluronic acid (HA) therapy with PRP-alone therapy in the treatment of knee osteoarthritis: a systematic review and meta-analysis. J Exp Orthop. 2021. https://doi.org/10.1186/s40634-021-00415-1.

54. Okoroha KR, Lu Y, Nwachukwu BU, Beletsky A, Patel BH, Verma NN, et al. How should we define clinically significant improvement on patient-reported outcomes measurement information system test for patients undergoing knee meniscal surgery? Arthroscopy. 2020;36(1):241–50.

55. Nwachukwu BU, Chang B, Rotter BZ, Kelly BT, Ranawat AS, Nawabi DH. Minimal clinically important difference and substantial clinical benefit after revision hip arthroscopy. Arthroscopy. 2018;34(6):1862–8.

56. Levy DM, Kuhns BD, Chahal J, Philpionn MJ, Kelly BT, Nho SJ. Hip arthroscopy outcomes with respect to patient acceptable symptomatic state and minimal clinically important difference. Arthroscopy. 2016;32(9):1877–86.

57. Goidi AK, Lalehzarian SP, Liu JN, Agarwalla A, Christian DR, Forsythe B, et al. Factors associated with clinically significant patient-reported outcomes after primary arthroscopic partial meniscectomy. Arthroscopy. 2019;35(5):1567–75.e3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.